financetom
Business
financetom
/
Business
/
Novelis Postpones IPO Due to Market Conditions
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Novelis Postpones IPO Due to Market Conditions
Jun 5, 2024 2:07 AM

04:57 AM EDT, 06/05/2024 (MT Newswires) -- Novelis ( NVL ) said Tuesday it is postponing its initial public offering "due to market conditions."

Novelis ( NVL ) said it will continue to evaluate the timing of the offering in the future.

The aluminum recycling company on May 28 said its sole shareholder, Hindalco Industries, was making an offering of 45 million shares priced at $18 to $21 per share.

Novelis ( NVL ) applied to list on the New York Stock Exchange under the ticker symbol NVL.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Trump unlikely to undo Biden's IRA climate legislation, TotalEnergies executive says
Trump unlikely to undo Biden's IRA climate legislation, TotalEnergies executive says
Nov 4, 2024
PARIS, Nov 4 (Reuters) - French oil major TotalEnergies does not anticipate that Donald Trump would pull the U.S. out of the Paris Agreement on climate change or undo Inflation Reduction Act (IRA) legislation if he became U.S. president again, the company's strategy director said on Monday. Aurelien Hamelle made the comments while presenting Total's energy outlook forecasting global demand...
Enveric Biosciences Secures New US Patents, Patent Allowances for EVM301 Portfolio
Enveric Biosciences Secures New US Patents, Patent Allowances for EVM301 Portfolio
Nov 4, 2024
11:11 AM EST, 11/04/2024 (MT Newswires) -- Enveric Biosciences ( ENVB ) said Monday that it secured five new patents and allowances for three more patent applications from the US Patent and Trademark Office for its EVM301 portfolio of molecules. The company said its EVM301 portfolio now has nine patents, including the newly issued ones. According to Enveric, EVM301's lead...
Constellation pursuing data centers at power plants despite regulatory setback
Constellation pursuing data centers at power plants despite regulatory setback
Nov 4, 2024
NEW YORK, Nov 4 (Reuters) - Constellation Energy ( CEG ) will continue to pursue deals to develop data centers on the sites of its U.S. power plants, days after federal regulators dealt a blow to the so-called co-located arrangements, company executives said on Monday. The Federal Energy Regulatory Commission on Friday rejected an agreement to increase the power capacity...
Ionis Pharmaceuticals Gets FDA Acceptance of New Drug Application for Angioedema Treatment
Ionis Pharmaceuticals Gets FDA Acceptance of New Drug Application for Angioedema Treatment
Nov 4, 2024
11:09 AM EST, 11/04/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Monday the US Food and Drug Administration has accepted for review a new drug application for donidalorsen for prophylaxis to prevent attacks of hereditary angioedema in adults and patients 12 years of age and older. The regulator has set an action date of Aug. 21, 2025, under...
Copyright 2023-2026 - www.financetom.com All Rights Reserved